非活动性乙型肝炎病毒表面抗原携带者的治疗  

Treatment of inactive hepatitis B surface antigen carriers

作　　者：曾达武[1] 朱月永[1] Zeng Dawu;Zhu Yueyong(Department of Hepatology,Hepatology Research Institute,the First Affiliated Hospital,Fujian Medical University,Clinical Research Center for Liver and Intestinal Diseases of Fujian Province,Fuzhou 350005,China)

机构地区：[1]福建医科大学附属第一医院肝内科、肝病研究所,福建省肝病与胃肠疾病临床医学研究中心,福州350005

出　　处：《国际流行病学传染病学杂志》2022年第4期225-231,共7页International Journal of Epidemiology and Infectious Disease

摘　　要：目前各国的慢性乙型肝炎防治指南(美国、欧洲、亚太、中国)对非活动性HBsAg携带状态(IHC)的治疗推荐意见并不完全一致。随着对乙型肝炎自然史的深入研究及抗病毒治疗方案不断探索,慢性HBV感染管理模式正在逐渐改变。各国针对是否扩大抗病毒治疗适应症进行深入的探索,本文就IHC的定义、是否应该抗病毒治疗、如何更精准判断IHC等进行了综述。The current clinical practice guidelines on the prevention and treatment for chronic hepatitis B are not completely consistent in the treatment recommendations for inactive HBsAg carrier(IHC).With the in-depth study of the natural history of hepatitis B and antiviral treatment,the management of chronic HBV infection is gradually changing.Countries have conducted exploration on whether to expand the indications of antiviral treatment.In this article,the definition of IHC,whether antiviral treatment should be carried out,and how to judge IHC more accurately are reviewed.

关 键 词：乙型肝炎表面抗原 非活动性HBsAg携带 抗病毒治疗 聚乙二醇干扰素 

分 类 号：R512.62[医药卫生—内科学]